Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active trials and study coordinator contact information, visit uvahealth.com/clinicaltrials.

New Trials Available at UVA

Congenital Pulmonic Valve Dysfunction (IRB-HSR #190037)

Multicenter Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 Transcatheter Heart Valve with the Alterra Adaptive Prestent – Continued Access (NCT03130777)
 
Primary Investigator: Scott Lim
Clinical Research Coordinator: Nicole Sprouse

Pediatric Oncology (IRB-HSR #190073)

AALL1732_A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLv (NCT03959085)
 
Primary Investigator: William Petersen
Clinical Research Coordinator: Candace Hudspeth

Cervical Cancer (IRB-HSR #200049)

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (NCT04221945)
 
Primary Investigator: Linda Duska
Clinical Research Coordinator: Sheena Clift

Mitral Regurgitation (IRB-HSR #200052)

Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Candidates for Surgery (REPAIR-MR) (NCT04198870)
 
Primary Investigator: Scott Lim
Clinical Research Coordinator: Linda Bryceland

Melanoma (IRB-HSR #21885)

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab VersusPembrolizumab in Patients with Previously Untreated Advanced Melanoma (NCT03815058)
 
Primary Investigator: Varinder Kaur
Clinical Research Coordinator: Adela Mahmutovic

Atrial Fibrillation (IRB-HSR #200097)

Evaluate Non-invasive mapping for Short interval measURE (ENSURE STUDY) 
 
Primary Investigator: James Mangrum
Clinical Research Coordinator: Hollis Phillips

Type 1 Diabetes (IRB-HSR #20754)

Pilot study to determine effect of exercise on insulin action in type 1 Diabetes
 
Primary Investigator: Rita Basu

Tricuspid Regurgitation (IRB-HSR #190061)

Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP II TR): A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation (NCT04097145)

Primary Investigator: Scott Lim, MD

Clinical Research Coordinator: Nicole J. Sprouse

Myasthenia Gravis (IRB-HSR #190089)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis (NCT04115293)

Primary Investigator: Sarah Jones

Clinical Research Coordinator: Mary Wagoner

Gynecologic Cancer (IRB-HSR #200011)

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (NCT04209855)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Benjamin Prabhu

Parkinson's Disease (IRB-HSR #200045)

A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease (NCT04291014)

Primary Investigator: Binit Shah

Clinical Research Coordinator: Stephanie Lowenhaupt

Cervical Cancer (IRB-HSR #200129)

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix (NCT03556839)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel

Leukemia (IRB-HSR #200133)

Palliative Care Oncology in Relapsed, Refractory, and High-Risk Leukemia Patients: Randomized Phase II Study (NCT04482894)

Primary Investigator: Karen Ballen

Clinical Research Coordinator: Emily Leytham

Gastrointestinal Cancer (IRB-HSR #200139)

A phase 3, open-label, randomized study of futibatinib versus germcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced cholagiocarcinoma harboring FGFR2 gene rearrangements (FOENIX-CCA3) (NCT04093362)

Primary Investigator: Paul Kunk

Clinical Research Coordinator: Sallie Mannen

Thoracic Oncology (IRB-HSR #200159)

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (NCT04092283)

Primary Investigator: Richard Hall

Clinical Research Coordinator: Gracie Hockenberry